{"id":10211,"date":"2020-05-21T10:46:29","date_gmt":"2020-05-21T08:46:29","guid":{"rendered":"https:\/\/idibell.cat\/en\/?page_id=10211"},"modified":"2025-05-21T16:21:20","modified_gmt":"2025-05-21T14:21:20","slug":"hematopoietic-stem-cell-biology-and-leukemogenesis","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/area-medicina-regenerativa-english\/regenerative-medicine-program\/hematopoietic-stem-cell-biology-and-leukemogenesis\/","title":{"rendered":"Hematopoietic Stem Cell Biology And Leukemogenesis"},"content":{"rendered":"\n

\n\t\tHematopoietic stem cell biology And leukemogenesis\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

Hematopoietic stem cells (HSCs) are considered the base of adult hematopoiesis. Currently, most of these hematological disorders are curable by HSC transplantation. However, the limited availability of optimally human matched donor remains a challenge, especially for individuals of non-Caucasian background or mixed ethnicity. Human pluripotent stem cells (PSCs), including embryonic stem cells (hESCs) and induced PSCs (hiPSCs), can differentiate in vitro into various hematopoietic cell type and could represent an ideal source of customized HSCs for clinical application. Furthermore, HSCs derived from patient-iPSCs not only represent an invaluable hematological disease modeling but might provide a cell-based platform for therapeutic screening. The production of engrafting HSCs from human PSCs will depend on the accurate recapitulation of embryonic hematopoiesis. <\/p>\n

23<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"Hematopoietic-Stem-Cell-Biology-And-Leukemogenesis\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Identification of developmental pathways involved in the generation of hematopoietic stem cells to direct the differentiation of pluripotent stem cells into clinically relevant hematopoietic cells<\/p>\n

Developing induced PSC based models of blood cancer stem cell development.<\/p>\n

These goals will be realized by combining genomics, transcriptomics, gene editing and cell biological techniques<\/p>\n

\u00a0<\/p>\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

– Bigas A, Palma LG, Kartha GM, Giorgetti A. Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development. Stem Cells Transl. Med. 2022. doi: 10.1093\/stcltm\/szac071<\/p>\n

– Kotmayer L, Romero Moya D, Marin Bejar O, Kozyra E, Catal\u00e0 A, Bigas A, Wlodarski MW, B\u00f6d\u00f6r C, Giorgetti A. GATA2 deficiency and MDS\/AML: Experimental strategies for disease modelling and future therapeutic prospects. Br J Haematol. 2022;199(4):482-495. doi:10.1111\/bjh.18330.<\/p>\n

– Pera J, Casta\u00f1o J, Casamitjana J, Giorgetti A, Romero Moya D. Generation of heterozygous SAMD9 CRISPR\/Cas9-edited iPSC line (ESi086-A-3), carrying p.I1567M mutation. Stem Cell Res. 2022;64102906-102906. doi:10.1016\/j.scr.2022.102906. IF:1,59.<\/p>\n

– Casta\u00f1o J, Romero Moya D, Richaud Patin Y, Giorgetti A. Generation of two heterozygous GATA2 CRISPR\/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency. Stem Cell Res. 2021;55102445-102445. doi:10.1016\/j.scr.2021.102445. IF:2,02.<\/p>\n

– Maroni G, Bassal MA, Krishnan I, Fhu CW, Savova V, Zilionis R, Maymi VA, Pandell N, Csizmadia E, Zhang JY, Storti B, Castano J, Panella R, Li J, Gustafson CE, Fox S, Levy RD, Meyerovitz CV, Tramontozzi PJ, Vermilya K, De Rienzo A, Crucitta S, Basseres DS, Weetall M, Branstrom A, Giorgetti A, Ciampi R, Del Re M, Danesi R, Bizzarri R, Yang H, Kocher O, Klein AM, Welner RS, Bueno R, Magli MC, Clohessy JG, Ali A, Tenen DG, Levantini E. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Commun Biol. 2021;4(1):370-370. doi:10.1038\/s42003-021-01897-6. IF:6,27.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t